CTSI’s Office of Discovery and Translation (ODAT) has released a special Request for Applications (RFA) to advance the development of promising early-stage therapeutics. The intention of funding is to better position these projects to be competitive for follow-on funding through other internal or external funding programs and for successful commercialization.
“ODAT provides early-stage funding to help put promising ideas and discoveries on the path toward improved human health,” states ODAT’s Director, Tucker LeBien, PhD. “Our goal with this RFA is to identify and support promising early-stage therapeutics in development at the University that can one day address significant unmet healthcare needs for patients.”
Projects that include development of novel therapeutics at the stage of product definition or product testing, such as lead identification and optimization, in vitro or in vivo proof of concept testing, and preclinical development, are eligible to apply for $50,000 in direct costs for one year.
Funding through this program is open to all qualifying UMN researchers from all campuses.
For more information view the RFA.